Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (4): 541-545    DOI: 10.31083/j.ceog.2020.04.5484
Original Research Previous articles | Next articles
Mode of delivery does not have a relationship with high-risk HPV positivity
G. Sel1, *(), A. Barut1, Ü. Özmen1, A. Y. Akdemir1, S. Harma2, B. Aynalı1, M. Harma1, M.İ. Harma1
1Zonguldak Bülent Ecevit University, Zonguldak, 67000, Turkey
2Demiroglu Bilim University, İstanbul, 34000, Turkey
Download:  PDF(305KB)  ( 266 ) Full text   ( 9 )
Export:  BibTeX | EndNote (RIS)      

Objective: This study aims to evaluate the delivery room data for patients who give birth with standard vaginal delivery and caesarean section (C/S), to estimate whether high-risk (HR) HPV status affected the mode of delivery. Methods: Between January 2014 and January 2018, 8,376 pregnant women gave birth in our hospital. Of 8,376 patients, 1,039 pregnant women were aged 30 years and older and had HPV results known. They had a singleton pregnancy and no contraindications for standard delivery. Results: C/S rates for all HR HPV groups were lower than for all HPV-negative groups. However, no statistically significant difference was found between HR HPV-positive and HPV-negative patients for C/S rates got all 987 patients (18.75% vs. 24.39%) (p = 0.463), 245 primiparous patients (50.0% vs. 59.83%) (p = 0.629) and 742 multiparous patients (11.53% vs. 12.56%) (p = 0.876). Conclusion: HR HPV positivity does not affect normal vaginal labour progress and does not statistically increase C/S rates at the labour ward. Therefore, HR HPV positivity should not be regarded as a negative risk factor for normal vaginal labour progress.

Key words:  HPV      C/S transition      NSVD      Labour      Delivery      High-risk HPV     
Submitted:  09 January 2020      Accepted:  24 June 2020      Published:  15 August 2020     
*Corresponding Author(s):  G. Sel     E-mail:

Cite this article: 

G. Sel, A. Barut, Ü. Özmen, A. Y. Akdemir, S. Harma, B. Aynalı, M. Harma, M.İ. Harma. Mode of delivery does not have a relationship with high-risk HPV positivity. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 541-545.

URL:     OR

Figure 1.  — Summary of the study groups’ formation

Table 1  — Summary of the study groups, NSVD and C/S rates.
Route of delivery All patients (987 patients) Multiparous (742 patients) Primiparous (245 patients)
Number of cases HR HPV + HPV p Number of cases HR HPV + HPV - p Number of cases HR HPV + HPV - p
NSVD 748 26 722 649 23 626 99 3 96
C/S 239 6 233 93 3 90 146 3 143
C/S Rate (%) 24.21 18.75 24.39 0.463 12.53 11.53 12.56 0.876 59.59 50 59.83 0.629
Count of patients
987 32 955 742 26 716 245 6
[1] Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al.: "Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women". Lancet, 2009, 374, 301-314.
doi: 10.1016/S0140-6736(09)61248-4 pmid: 19586656
[2] Bernard H.U.: "Taxonomy and phylogeny of papillomaviruses: an overview and recent developments". Infect Genet Evol, 2013, 18, 357-361.
doi: 10.1016/j.meegid.2013.03.011
[3] De Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur H.: "Class Papillomaviruses". Virology, 2004, 324, 17-27.
doi: 10.1016/j.virol.2004.03.033 pmid: 15183049
[4] Centers for Disease Control and Prevention. Genital HPV Infection Fact Sheet. Human Papillomavirus (HPV). 2018. (25 Jan 2020, date last accessed).
[5] Gultekin M., Zayifoglu K.M., Kucukyildiz I., Dundar S., Boztas G., Semra T.H., et al.: "Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women". Int J Cancer, 2018, 142, 1952-1958.
doi: 10.1002/ijc.31212 pmid: 29235108
[6] Freitas A.C., Mariz F.C., Silva M.A., Jesus A.L.S.: "Human papillomavirus vertical transmissio.: review of current data". Clin Infect Dis, 2013, 56, 1451-1456.
doi: 10.1093/cid/cit066
[7] Lee S.M., Park J.S., Norwitz E.R., Koo J.N., Oh I.H., Park J.W., et al.: "Risk of vertical transmission of human papillomavirus throughout pregnancy: a prospective study". PloS one, 2013, 8, e66368.
doi: 10.1371/journal.pone.0066368 pmid: 23785495
[8] Zuo Z., Goel S., Carter J.E.: "Association of cervical cytology and HPV DNA status during pregnancy with placental abnormalities and preterm birth". Am J Clin Pathol, 2011, 136, 260-265.
doi: 10.1309/AJCP93JMIUEKRPIW
[9] Gomez L.M., Ma Y., Ho C., McGrath C.M., Nelson D.B., Parry S.: "Placental infection with human papillomavirus is associated with spontaneous preterm delivery". Hum Reprod, 2008, 23, 709-715.
doi: 10.1093/humrep/dem404 pmid: 18184644
[10] Cho G., Min K.J., Hong H.R., Kim S., Hong J.H., Lee J.K., et al.: "High-risk human papillomavirus infection is associated with premature rupture of membranes". BMC Pregnancy Childbirth, 2013, 13, 173.
doi: 10.1186/1471-2393-13-173 pmid: 24011340
[11] Hermonat P.L., Kechelava S., Lowery C.L., Korourian S.: "Trophoblasts are the preferential target for human papilloma virus infection in spontaneously aborted products of conception". Hum Pathol, 1998, 29, 170-174.
doi: 10.1016/s0046-8177(98)90228-3 pmid: 9490277
[12] Weinstock H., Berman S., Cates Jr. W.: "Sexually transmitted diseases among American yout.: incidence and prevalence estimates, 2000". Perspect Sex Reprod Health, 2004, 36, 6-10.
doi: 10.1363/psrh.36.6.04 pmid: 14982671
[13] Romero R., Espinoza J., Kusanovic J.P., Gotsch F., Hassan S., Erez O., et al.: "The preterm parturition syndrome". BJOG, 2006, 113, 17-42.
doi: 10.1111/j.1471-0528.2006.00879.x pmid: 16529565
[14] Donati L., Di Vico A., Nucci M., Quagliozzi L., Spagnuolo T., Labianca A., et al.: "Vaginal microbial flora and outcome of pregnancy". Arch Gynecol Obstet, 2010, 281, 589-600.
doi: 10.1007/s00404-009-1318-3
[15] Giakoumelou S., Wheelhouse N., Cuschieri K., Entrican G., Howie S.E., Horne A.W.: "The role of infection in miscarriage". Hum Reprod Update, 2016, 22, 116-133.
doi: 10.1093/humupd/dmv041 pmid: 26386469
[16] Manuck T.A., Esplin M.S., Biggio J., Bukowski R., Parry S., Zhang H., et al.: "The phenotype of spontaneous preterm birth: application of a clinical phenotyping tool". Am J Obstet Gynecol, 2015, 212, 487-e1.
doi: 10.1016/j.ajog.2015.02.010 pmid: 25687564
[17] Niyibizi J., Zanré N., Mayrand M.H., Trottier H.: "The association between adverse pregnancy outcomes and maternal human papillomavirus infectio.: a systematic review protocol". Syst Rev, 2017, 6, 53.
doi: 10.1186/s13643-017-0443-5 pmid: 28284227
[18] Rustveld L.O., Kelsey S.F., Sharma R.: "Association between maternal infections and preeclampsi.: a systematic review of epidemiologic studies". Matern Child Health J, 2008, 12, 223-242.
doi: 10.1007/s10995-007-0224-1 pmid: 17577649
[19] Nimrodi M., Kleitman V., Wainstock T., Gemer O., Meirovitz M., Maymon E., et al.: "The association between cervical inflammation and histologic evidence of HPV in PAP smears and adverse pregnancy outcome in low risk population". Eur J Obstet Gynecol Reprod Biol, 2018, 225, 160-165.
doi: 10.1016/j.ejogrb.2018.04.023 pmid: 29727786
[20] Inal M.M., Köse S., Yildirim Y., Ozdemir Y., Töz E., Ertopçu K., et al.: "The relationship between human papillomavirus infection and cervical intraepithelial neoplasia in Turkish women". Int J Gynecol Cancer., 2007, 17, 1266-1270.
doi: 10.1111/j.1525-1438.2007.00944.x pmid: 17442019
[21] Tuncer Z.S., Basaran M., Ustaçelebi S., Kuzey G.M.: "High-risk human papilloma virus (HPV) infection determined by hybrid capture ii assay in a Turkish University Hospital Outpatient Clinic". Obstet Gynaecol Reprod Med, 2006, 12, 129-134.
[22] Ozçelik B., Serin I.S., Gökahmetoğlu S., Başbuğ M., Erez R.: "Human papillomavirus frequency of women at low risk of developing cervical cance.: a preliminary study from a Turkish University Hospital". Eur J Gynaecol Oncol, 2003, 24, 157-159.
pmid: 12701968
[23] Seçkin S., Aksoy F., Yıldırım M.: "Servikal Smearlerde HPV İnfeksiyonu Görülme İndisansı". Ankara Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, 1996, 36, 101-103. [In Turkish]
[24] Dursun P., Ayhan A., Mutlu L., Çağlar M., Haberal A., Güngör T., et al.: "HPV types in Turke.: multicenter hospital based evaluation of 6388 patients in Turkish Gynecologic Oncology Group Centers". Turk Patoloji Derg, 2013, 29, 210-216.
doi: 10.5146/tjpath.2013.01188 pmid: 24022311
[25] Kelly R.W.: "Inflammatory mediators and cervical ripening". J Reprod Immunol, 2002, 57, 217-224.
doi: 10.1016/s0165-0378(02)00007-4 pmid: 12385844
[26] Brummer O., Böhmer G., Hollwitz B., Flemming P., Petry K-U., Kühnle HJ.Go.: "MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation—an immunohistochemical study". Gynecol Oncol, 2002, 84, 222-227.
doi: 10.1006/gyno.2001.6413
[27] Davidson B., Goldberg I., Kopolovic J., Lerner-Geva L., Gotlieb W.H., Ben-Baruch G., et al.: "MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma—a clinicopathological study using immuohistochemistry and mRNA in situ hybridization". Gynecol Oncol, 1999, 73, 372-382.
doi: 10.1006/gyno.1999.5381 pmid: 10366463
[1] Marcelo Epsztein Kanczuk, Nicholas J Lightfoot, Alison Pighills, Antony Ji, Casey Steele, Daniel Bartlett. The time to perform spinal or general anaesthesia in COVID-19 positive parturients requiring emergency caesarean delivery: a prospective crossover simulation study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1099-1106.
[2] Eser Ağar, Seda Şahin Aker. Effect of sexual dysfunction on women's preference for delivery methods: a social media-based survey[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1154-1161.
[3] Uros Visic, Tatjana Stopar Pintaric, Tit Albreht, Iva Blajic, Miha Lucovnik. Multimodal stepwise analgesia for reducing opioid consumption after cesarean delivery[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1162-1166.
[4] Valeria Filippi, Luigi Raio, Sophia Amylidi-Mohr, Rudolf Tschudi, Daniele Bolla. Epidural analgesia at trial of labour after caesarean section. A retrospective cohort study over 12 years[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 913-917.
[5] Aizura Syafinaz Ahmad Adlan, Vikneswaran Virasamy, Doris Ng Sin-Wen, Noor Azmi Mat Adenan. 8 am versus 8 pm labour induction with dinoprostone vaginal tablets in term pregnancies with unfavourable cervices—a randomised controlled trial[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 523-527.
[6] Batool Ali H. Alkhazal, Majed Abdullah Halawani, Ibtihal Omar Alsahabi, Hassan S.O. Abduljabbar. The preferred mode of delivery among primigravida Middle Eastern Women. A questionnaire based study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 567-571.
[7] Faris Mujezinović, Veronika Anzeljc, Monika Sobočan, Iztok Takač. Do women in Slovenia prefer vaginal birth after prior caesarean and what hinders its successful outcome? A single institution retrospective analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 607-614.
[8] Veronika Anzeljc, Faris Mujezinović. Caesarean sections and outcomes of labor induction after the introduction of a new intravaginal device: retrospective analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 615-627.
[9] Antonio Coviello, Concetta Posillipo, Ludovica Golino, Carlo De Angelis, Elisabetta Gragnano, Gabriele Saccone, Marilena Ianniello, Gaetano Castellano, Annachiara Marra, Alfredo Maresca, Maria Vargas, Giuseppe Servillo. Anesthesiologic management of pregnant women with SARS-COV-2 infection undergoing cesarean delivery[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 628-630.
[10] Ugo Indraccolo, Maria Giulia Lombana Marino, Beatrice Bianchi, Silvia Catagini, Danila Morano, Pantaleo Greco. Symphysis-fundal height correlates with adverse delivery and neonatal outcomes in induced full-term and premature pregnancies[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 637-641.
[11] Jakub Mlodawski, Marta Mlodawska, Justyna Armanska. Dinoprostone vaginal insert vs the Foley catheter in labor induction. Observational study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 665-669.
[12] Bara'a Samara, Anton R. Sabella. The knowledge and attitudes of Palestinian women towards different childbirth delivery options[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 138-143.
[13] B. Kim, S.H. Hong, J.H. Kim, M.Y. Kang, M.R. Rhee, J. Kim, K.J. Kim, H.A. Lee. Giant ventral hernia immediately after vaginal twin delivery[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 988-990.
[14] I.F. Urunsak, U.K. Gulec, E. Eser, M. Sucu, C. Akcabay, S. Buyukkurt. The role of dinoprostone for labor induction in postterm and high-risk term pregnancies[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 664-668.
[15] S. Srisukho, K. Srisupundit, T. Tongsong. Fulfillment of the criteria for diagnosis of cephalo-pelvic disproportion: ACOG guidelines[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 500-504.
No Suggested Reading articles found!